11/13/2008 | CVDDSS | DOV Pharmaceutical needs to find capital by December to keep clinical trial, operations going
|
5/15/2008 | DDSS | DOV needs more cash to meet capital requirements beyond early 2009
|
3/31/2008 | DDSS | DOV Pharmaceutical says capital needs threaten going-concern status beyond November 2008
|
1/4/2008 | DDSS | DOV Pharmaceutical to limit focus, reduce workforce to save cash
|
11/7/2007 | CVDDSS | DOV Pharmaceutical says capital needs threaten going concern status
|
8/8/2007 | CVDDSS | DOV Pharmaceutical funding needs threaten going-concern status beyond Dec. 31
|
3/30/2007 | CVDDSS | DOV Pharmaceutical repays $2.5 million accelerated debentures; going concern status threatened
|
3/15/2007 | CVDDSS | DOV Pharmaceutical holders tender 96.4% of 2.5% debentures under exchange offer
|
3/8/2007 | CVDDSS | DOV Pharmaceutical modifies, extends exchange offer for 2.5% convertibles
|
3/6/2007 | CVDD | DOV Pharmaceutical extends 2.5% convertibles exchange offer to March 7
|
1/29/2007 | CVDDSS | DOV Pharmaceutical launches exchange offer for 2.5% convertibles
|
1/25/2007 | CVDDSS | DOV Pharmaceutical restructuring agreement includes exchange offer for 2.5% convertibles
|
1/17/2007 | DDSS | DOV Pharmaceutical agrees to allow XTL Development to use product candidate bicifadine
|
1/3/2007 | CV | Market Commentary: Nabors falls in line on profit warning; Ford climbs with sales numbers; Sirius, XM marked higher on news
|
1/3/2007 | CVDDSS | DOV unable to buy back any 2.5% convertibles during required offer, causing event of default
|
11/9/2006 | BTCVDD | DOV Pharmaceutical to launch required 2.50% convertible buyback offer Friday
|
10/26/2006 | BT | Market Commentary: Achillion gains on debut; Cadence slips; DOV Pharma nosedives; Celgene better; Renovis falls 76%
|
10/26/2006 | BTCVDD | DOV Pharmaceutical required 2.5% convertible buyback offer may force company to file bankruptcy
|
10/17/2006 | BT | Market Commentary: Icos gains 16% on Lilly buyout; Millennium forfeits AnorMED; InterMune rises 25%; OSI better
|
10/11/2006 | CV | Market Commentary: DOV gains on delisting speculation; Nabors slips amid buyout rumors; Harrah's lower with stock
|
10/10/2006 | BT | Market Commentary: AnorMED gains 5% as Genzyme bests Millennium bid; DOV sinks 9% on hiring HSBC, up after close
|
8/30/2006 | BT | DOV fails to regain compliance with Nasdaq listing requirements
|
8/17/2006 | BT | Market Commentary: Neurocrine adds 10%; NPS up on 'Soros factor'; Vivus higher; Genitope slides 4%
|
8/15/2006 | BT | Merrill terminates its coverage of DOV
|
8/9/2006 | BT | DOV says Q2 net loss hits $20.6 million, phase 3 bicifadine trial fails to meet endpoint
|
8/9/2006 | BTCVDD | DOV must regain Nasdaq listing compliance to avoid 2.5% convertibles tender offer
|
7/31/2006 | BT | DOV fails to comply with Nasdaq continued listing requirements
|
7/27/2006 | BTCV | DOV Pharmaceutical exchanges $10 million 2.5% convertible debentures for stock
|
7/26/2006 | BT | Market Commentary: DOV comes off highs; Neurocrine extends losses after hours; bird flu stocks fly; NicOx rises
|
7/26/2006 | BT | DOV says bicifadine eliminates carcinogens
|
7/18/2006 | BT | Market Commentary: Tercica up 12%, Insmed rises 9%; Neurocrine closes weaker; Pharma Product up; New River deal emerges
|
7/10/2006 | BT | Market Commentary: Connetics drops 33% on lowered forecast; Antigenics off 5%; Depomed off; Acadia gains
|
7/6/2006 | BT | Market Commentary: Par shares plunge, convertible up with restatement; Savient up on new CFO; Gene Logic moves up
|
7/5/2006 | BT | Market Commentary: DOV seesaws on CEO exit, closes higher; Neurocrine slides further; Insmed drops 8%; Tercica off 1%
|
7/5/2006 | BT | DOV Pharmaceutical CEO resigns, senior management team reorganized
|
6/27/2006 | BT | Market Commentary: Insmed drops 11%; Vasogen up slightly; Anadys falls more; DOV, Discovery Labs up; Genelabs gains
|
6/23/2006 | BT | Market Commentary: Neurocrine, DOV fall on Pfizer nixing indiplon funding; Endo rises 10%, Penwest gains 37%
|
6/19/2006 | BT | Market Commentary: Peregrine up; Micrus off; DOV drops 11%; Neurocrine off 7%; American Medical plans $325 million bond
|
5/23/2006 | BT | Merrill maintains DOV at sell
|
5/22/2006 | BT | Market Commentary: Adventrx gains after pulling deal; Dyax gains, Icos slips on pact; Cell Therapeutics declines 7%
|
5/22/2006 | BT | DOV blames "unusually high" placebo response for Bicifadine trial failure, sees some benefits
|
5/19/2006 | BT | DOV cuts workforce, postpones bicifadine development
|
5/19/2006 | BT | Market Commentary: Illumina gains after spot sale; Neurocrine, DOV mixed; Pozen pounded; Alkermes dips, settles higher
|
5/18/2006 | BT | Market Commentary: Neurocrine piles on more losses; DOV adds back 10%; Celgene sees buying on dip; Exelixis up
|
5/18/2006 | CV | Market Commentary: Enzon climbs, Nabors flat on debuts; American Axle gains on conversion expectations; DOV slides further
|
5/17/2006 | BT | Market Commentary: Vivus up 15%; Hana off 10% on PIPE deal; Restore gains on debut; NxStage drops on follow-on deal
|
5/16/2006 | BT | Dov down to sell by Merrill
|
5/16/2006 | BT | Market Commentary: Neurocrine, DOV dive; Novavax, Generex dive amid noise of exits; Adventrx slips modestly on deal
|
5/16/2006 | CV | Market Commentary: American Axle surges on possible loophole; DOV Pharmaceuticals falls, Sepracor gains on drug's rejection
|
5/12/2006 | BT | DOV held at neutral by Merrill
|
4/28/2006 | BT | Market Commentary: Neurocrine drops as data digested; Somaxon higher as buyers step in; Spectranetics up; Sonus soars 8%
|
4/26/2006 | BT | Market Commentary: Inspire trial launch brings buyers; Avigen players hopeful; Applera units mixed; LifeCell lifted 15%
|
4/25/2006 | BT | Dov downgraded to neutral by Merrill
|
4/25/2006 | BT | Market Commentary: Serologicals, Millipore both up; other services names dip; DOV, Discovery dive; Neurocrine off
|
4/25/2006 | CV | Market Commentary: Serologicals weakens on hedged basis; JetBlue, Level 3 gain on results; Dov falls on drug trial woes
|
4/24/2006 | BT | Market Commentary: DOV, Discovery Labs off huge after close; 3 deals emerge; GW up big; Ariad off on Amgen suit
|
4/24/2006 | BT | DOV phase 3 study of analgesic bicifadine fails to meet primary endpoint in back pain study
|
4/11/2006 | BT | DOV receives notice of patent allowance for crystalline form of novel analgesic, bicifadine
|
4/6/2006 | BT | Merrill initiates Dov at buy rating
|
3/8/2006 | BT | DOV Pharmaceutical says net loss up 61% to $53 million in 2005
|
2/13/2006 | BT | Market Commentary: Amgen up after-hours as $4 billion convert emerges; Genentech off; Adolor down on deal; Alnylam up
|
2/13/2006 | BT | DOV: FDA says studies sufficient to submit NDA for bicifadine
|
2/7/2006 | BT | DOV Pharmaceutical begins phase 2 trial of bicifadine for osteoarthritis
|
2/6/2006 | BT | DOV Pharmaceutical begins phase 2 trial of bicifadine for neuropathic pain
|
2/6/2006 | BT | Market Commentary: OSI Pharma players debate new policy; Serono slips as 'for sale' sign stands; CuraGen gains 11%
|
2/3/2006 | CV | Market Commentary: UBS AG sets record with $2 billion of 18-month exchangeables; Amazon.com converts hold steady
|
2/3/2006 | BT | Market Commentary: DOV rises; ImmunoGen tumbles; OccuLogix, TLC-Vision plunge; Sirna spikes; CryoCor crumbles
|
2/2/2006 | BT | DOV completes enrollment in its phase 3 clinical trial of bicifadine for back pain
|
1/9/2006 | BT | Market Commentary: Human Genome, Amgen higher on license pact; Alnylam soars on 2006 view; NPS, Oscient up big
|
12/19/2005 | BT | DOV begins second phase 1b trial of triple reuptake inhibitor antidepressant
|
12/12/2005 | BT | DOV study of bicifadine for back pain supported by independent analysis
|
12/5/2005 | BT | DOV Pharmaceutical files $100 million stock shelf
|
11/3/2005 | BT | DOV Pharmaceutical says open-label study shows bicifadine effective in treating chronic low back pain
|
9/12/2005 | BT | Geron joins Myogen for Thursday; Cell Genesys up on back of Geron; OSI Pharma plummets on Tarceva
|
9/12/2005 | CV | Market Commentary: Northwest drops as other airline convertibles trade mixed; software names see better bids
|
8/26/2005 | BT | Market Commentary: AtheroGenics joins Amylin in gains linked to takeover chatter; Isis easier; DOV Pharma dives
|
8/26/2005 | CV | Market Commentary: DOV Pharmaceutical convertibles tumble; Atherogenics adds; Agilent active on call news
|
8/10/2005 | BT | DOV Pharma kept by Global at overweight
|
7/18/2005 | BT | DOV Pharma initiated by Global Crown at overweight
|
7/14/2005 | BT | Market Commentary: Genentech active; CryoCor IPO trades up, sinks; Mylan prices tight, center; BioMarin off on follow-on
|
7/1/2005 | BT | Market Commentary: Altana crushed by Pfizer news; Cubist, Corixa rise in thin market, Millennium off; Cephalon higher
|
5/26/2005 | CV | Market Commentary: Ford, GM better on short covering; airlines also firmer; techs rally but Computer Associates off after bell
|
1/12/2005 | CV | Market Commentary: Level 3 higher on job cuts; CenturyTel off; Kodak up; Advanced Micro rebounds
|
1/4/2005 | CV | DOV Pharmaceutical greenshoe exercised, raising convertibles to $80 million
|
12/17/2004 | CV | New Issue: DOV Pharmaceutical sells $65 million convertible to yield 2.5%, up 30%
|
12/17/2004 | CV | Market Commentary: IVAX reoffered at 98.5; BearingPoint up to 101.25; Charter up on M&A talk; PSEG soars on buyout buzz
|
12/16/2004 | CV | Market Commentary: Abgenix goes to 104; NRG climbs to 106.5; Gateway, BearingPoint up when-issued
|
12/16/2004 | CV | DOV Pharmaceutical prices $65 million convertibles to yield 2.5%, up 30%
|
12/15/2004 | CV | Market Commentary: Abgenix bid at 102.5 in gray market; NRG goes to 105; Gateway, Dover, BearingPoint rush market
|